Dr. Ke Chen, our Vice President and Head of API Late phase Process R&D, weighs in on challenges impacting supply management of orphan drugs in an industry roundtable hosted by DCAT Value Chain Insights. Low-volume drug is one of the many cases where challenges are ahead. Nonetheless, our scientists rise to the challenges, fulfilling our mission – every drug can be made and every disease can be treated.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.